Abstract
Increasing the total dose or the dose intensity of platinum does not improve survival in women with ovarian cancer. High-dose chemotherapy with hematologic support has not been shown to be more effective than standard-dose chemotherapy. Regional dose intensity, through intraperitoneal chemotherapy, may have a role in the treatment of advanced ovarian cancer. Further studies are needed to identify the optimal combination of agents, in addition to a platinum and a taxane, to be used in primary therapy for ovarian cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 54-58 |
Number of pages | 5 |
Journal | Current oncology reports |
Volume | 1 |
Issue number | 1 |
DOIs | |
State | Published - Sep 1999 |
ASJC Scopus subject areas
- Oncology